VentriPoint Diagnostics (TSE:VPT) has released an update.
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Ventripoint Diagnostics and ASCEND Cardiovascular have signed a term sheet for a non-exclusive license to integrate Ventripoint’s VMS+ technology into ASCEND’s Gen3Echo platform, aiming to enhance cardiovascular diagnostics. This collaboration promises to improve diagnostic accuracy and streamline workflows for echocardiographers by combining cutting-edge AI and machine learning technologies.
For further insights into TSE:VPT stock, check out TipRanks’ Stock Analysis page.